On 8 October, the EU negotiated 200 million doses of the same vaccine from Johnson & Johnson; it has the option to buy up to 400 million doses. At the end of September, Johnson & Johnson’s single dose coronavirus vaccine entered late-stage trials. Dr. Anthony Fauci, director of the National Institute for Allergy and Infectious Disease, said the Johnson & Johnson vaccine would be “especially useful” if it could be showed to control the pandemic through just one single dose. There are currently four pharmaceutical companies testing vaccines but Johnson & Johnson has several advantages, even though it is further behind the other three. Johnson & Johnson has also announced plans to allocate up to 500 million doses towards international efforts for lower income countries.

Source: Forbes October 09, 2020 12:45 UTC